Pneumococcal infective endocarditis in Brazil: a multicenter study on a severe condition

Braz J Infect Dis. 2024 Jul-Aug;28(4):103837. doi: 10.1016/j.bjid.2024.103837. Epub 2024 Jul 4.

Abstract

Background: Streptococcus pneumoniae bacteremia may result in Infective Endocarditis (IE). In the pre-antibiotic era, it caused 10 %‒15 % of IE, decreasing to < 3 % after penicillin availability. Although infrequent, it causes aggressive disease.

Methods: Retrospective analysis of endocarditis databases, prospectively implemented in 4 Brazilian institutions, 2005‒2023.

Results: From the prospective cohorts comprising 2321 adult patients with IE, we identified 11 (0.47%) with pneumococcal IE. Males represented 7/11 and mean age was 54 years (22‒77). All had native valve involvement; perivalvular abscess was present in 6/11. Only one patient had concurrent meningitis. Beta-lactams were the antibiotics used in 10/11. All had surgical indication, but only 6 had it, as the others were seriously ill. Overall, in hospital mortality was 6/11, but only 1/6 of those who underwent surgery died, compared to 5/5 of those who had an indication for surgery and did not have it.

Conclusions: The high mortality rates and need for surgical intervention emphasize the need to promptly identify and manage pneumococcal endocarditis. Physicians ought to recommend vaccination to all patients at risk for severe pneumococcal disease.

Keywords: Infective endocarditis; Mortality; Streptococcus pneumoniae; Surgery.

Publication types

  • Multicenter Study

MeSH terms

  • Adult
  • Aged
  • Anti-Bacterial Agents / therapeutic use
  • Brazil / epidemiology
  • Endocarditis, Bacterial* / microbiology
  • Endocarditis, Bacterial* / mortality
  • Female
  • Hospital Mortality
  • Humans
  • Male
  • Middle Aged
  • Pneumococcal Infections* / drug therapy
  • Pneumococcal Infections* / mortality
  • Prospective Studies
  • Retrospective Studies
  • Risk Factors
  • Severity of Illness Index
  • Streptococcus pneumoniae / isolation & purification
  • Young Adult

Substances

  • Anti-Bacterial Agents